The prognostic value of p53 abnormal expression in non-myoinvasive endometrial cancer: a retrospective comparative study according to p53 status and myometrial invasion - PubMed
4 hours ago
- #Endometrial Cancer
- #p53
- #Molecular Classification
- Study assesses oncologic outcomes of p53 abnormal expression in non-myoinvasive endometrial cancer.
- Retrospective evaluation of 473 patients, focusing on 81 with p53abn non-myoinvasive tumors.
- p53abn non-myoinvasive group showed 88.1% 5-year recurrence-free survival, with 75% distant recurrences.
- No difference in overall survival between p53abn with and without myometrial invasion.
- Recurrence-free survival worse in p53abn with <50% myoinvasion compared to non-myoinvasive.
- p53abn non-myoinvasive tumors had shorter overall survival when compared to all p53wt cases combined.
- Abnormal p53 expression linked to higher recurrence risk and shorter survival.
- Myometrial invasion not predictive of overall or recurrence-free survival.
- Highlights the aggressive nature of p53abn tumors, even without myometrial invasion.
- Emphasizes the importance of molecular assessment in endometrium-confined tumors.